tiprankstipranks
Q32 Bio announces corporate restructuring to focus on bempikibart
PremiumThe FlyQ32 Bio announces corporate restructuring to focus on bempikibart
12d ago
Q32 Bio Advances Clinical Trials for Growth Opportunities
Premium
Company Announcements
Q32 Bio Advances Clinical Trials for Growth Opportunities
1M ago
Q32 Bio price target lowered to $22 from $64 at BMO Capital
Premium
The Fly
Q32 Bio price target lowered to $22 from $64 at BMO Capital
2M ago
Q32 Bio price target lowered to $20 from $85 at Piper Sandler
PremiumThe FlyQ32 Bio price target lowered to $20 from $85 at Piper Sandler
2M ago
Q32 Bio downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Q32 Bio downgraded to Market Perform from Outperform at Leerink
2M ago
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
Premium
The Fly
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
2M ago
Q32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs
PremiumCompany AnnouncementsQ32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs
4M ago
Q32 Bio reports Q3 EPS ($1.46), consensus ($1.40)
Premium
The Fly
Q32 Bio reports Q3 EPS ($1.46), consensus ($1.40)
4M ago
Q32 Bio initiated with a Strong Buy at Raymond James
Premium
The Fly
Q32 Bio initiated with a Strong Buy at Raymond James
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100